IGF-1: What Your Number Changes About Your Treatment

What IGF-1 Actually Measures

IGF-1, also called somatomedin C, is a peptide hormone produced primarily by the liver in response to growth hormone stimulation. Your IGF-1 number is not a snapshot of GH itself. It reflects the cumulative effect of GH on your liver over the preceding 24-48 hours, making it a far more stable and clinically useful marker than a single GH draw [1].

GH is released in pulses, mostly during deep sleep. A random serum GH level can swing from <0.1 to 20 ng/mL within the same hour. IGF-1, by contrast, has a half-life of approximately 12-15 hours when bound to its carrier protein IGFBP-3 [2]. That stability is precisely why the Endocrine Society's 2011 clinical practice guideline recommends IGF-1 (not random GH) as the primary monitoring tool during GH replacement therapy [3].

The liver accounts for roughly 75% of circulating IGF-1 [2]. The remaining fraction comes from bone, muscle, and other tissues where it acts locally. When your clinician orders an IGF-1 level, they are reading your body's integrated GH signal. A low number means insufficient GH effect at the tissue level. A high number means excessive GH stimulation. Both extremes change what happens next in your treatment.

Normal IGF-1 Ranges by Age

The reference range for IGF-1 is not a single number. It shifts substantially across the lifespan. Peak levels occur during puberty, often exceeding 400 ng/mL, and decline steadily after age 25 [4].

For adults receiving GH or GH peptide therapy, the Endocrine Society guideline specifies that the dose should be titrated to maintain serum IGF-1 "in the upper half of the normal range" specific to age and sex [3]. The American Association of Clinical Endocrinology (AACE) 2019 update echoes this target: keep IGF-1 between the 50th and 97.5th percentile for the patient's age-sex cohort [5].

Here is a general approximation (values differ slightly between assays):

• Ages 20-30: 117-329 ng/mL (male), 110-362 ng/mL (female)
• Ages 31-40: 115-307 ng/mL (male), 101-267 ng/mL (female)
• Ages 41-50: 94-269 ng/mL (male), 89-234 ng/mL (female)
• Ages 51-60: 81-225 ng/mL (male), 75-204 ng/mL (female)
• Ages 61-70: 69-200 ng/mL (male), 63-188 ng/mL (female)

These numbers come from large reference populations. Mayo Clinic and Quest Diagnostics publish their own validated ranges that may differ by 10-15% depending on the immunoassay platform used [4]. Always compare your result to the reference range printed on your specific lab report, not to a number you found online.

How a High IGF-1 Changes Your Protocol

An IGF-1 above the age-adjusted reference ceiling is the clearest signal to reduce your dose. This is not optional.

Sustained supraphysiologic IGF-1 is associated with increased risk of fluid retention, joint pain, carpal tunnel syndrome, and insulin resistance [3]. Epidemiologic data from the European Journal of Endocrinology (2012, N=6,840) found that patients with acromegaly whose IGF-1 remained above the upper limit of normal had a standardized mortality ratio of 1.9 compared to the general population [6]. While GH peptide therapy patients are not acromegalic, the biology of excess IGF-1 signaling is the same.

The AACE/ACE 2019 guideline states that when IGF-1 exceeds the upper limit, "the GH dose should be decreased" and IGF-1 rechecked in 4-6 weeks [5]. Common clinical responses to a high IGF-1 include:

• Reducing the GH peptide dose by 20-30%
• Switching from daily to 5-days-on/2-days-off dosing
• Holding therapy entirely if IGF-1 exceeds 1.5x the upper limit
• Screening fasting glucose and HbA1c to assess metabolic impact

The relationship between IGF-1 and insulin resistance deserves attention. A 2020 analysis in the Journal of Clinical Endocrinology & Metabolism (N=2,479) demonstrated that IGF-1 levels in the highest quartile were associated with a 34% increased risk of developing type 2 diabetes over 9 years of follow-up [7]. Your prescriber should be checking fasting glucose alongside IGF-1 during titration.

How a Low IGF-1 Changes Your Protocol

A low IGF-1 (below the 50th percentile for your age) during active GH peptide therapy suggests the current dose is insufficient, but the clinical response is not always a simple dose increase.

Your clinician should first rule out confounding factors. Malnutrition, liver disease, poorly controlled diabetes, hypothyroidism, and high-dose estrogen therapy all suppress IGF-1 independently of GH status [8]. The Endocrine Society guideline specifically warns that oral estrogen lowers IGF-1 by 30-50% compared to transdermal estrogen at equivalent doses, a finding confirmed in a randomized crossover trial (N=18) published in JCEM [9]. Women on oral contraceptives or oral HRT will often show misleadingly low IGF-1 levels.

If confounders are excluded, the typical next steps include:

• Increasing the GH peptide dose by 25-50 mcg increments (for CJC-1295/ipamorelin protocols)
• Reassessing adherence and injection timing (pre-bedtime dosing produces higher GH pulses)
• Rechecking IGF-1 in 4-6 weeks after the dose change
• Ordering a GH stimulation test if IGF-1 remains flat despite adequate dosing, to evaluate for true GH deficiency requiring recombinant GH

A persistently low IGF-1 that does not respond to secretagogue therapy may indicate pituitary insufficiency. In that scenario, GH peptides that rely on stimulating the pituitary (like GHRH analogs) will not work, and direct recombinant GH replacement becomes necessary [3].

IGF-1 as the Dose-Titration Anchor in GH Peptide Therapy

Every modern GH replacement protocol uses IGF-1 as its titration anchor. The days of weight-based GH dosing are over.

The Endocrine Society's 2011 guideline replaced the older weight-based approach with individualized IGF-1-guided titration after data showed that weight-based dosing produced supraphysiologic IGF-1 in over 50% of patients [3]. The recommended method: start low, increase gradually, and let the IGF-1 level dictate each adjustment.

For GH peptide protocols (CJC-1295/ipamorelin, tesamorelin, sermorelin), the same principle applies. A typical titration schedule looks like this:

Baseline. Draw IGF-1 before starting therapy. This establishes your set point.

Week 4-6. Redraw IGF-1. If the level has risen into the upper half of the age-adjusted range, hold the current dose. If it has risen but remains below the 50th percentile, increase by one increment.

Week 10-12. Confirm IGF-1 stability. If the level has overshot, reduce the dose.

Maintenance. Once the target range is achieved, recheck IGF-1 every 3-6 months [5].

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society clinical practice guideline, has stated: "IGF-1 is the best available surrogate for integrated GH secretion. We dose-adjust based on IGF-1, not on symptoms alone" [3].

The AACE 2019 consensus reinforces this: "Serum IGF-1 concentration should be used as the biomarker for dose titration, maintained in the age- and sex-appropriate normal range" [5].

What IGF-1 Means Beyond GH Therapy

IGF-1 is not just a GH therapy marker. Its level carries independent clinical information.

Body composition. IGF-1 in the upper-normal range is associated with greater lean mass and lower visceral fat. A 2009 study in JCEM (N=2,189) found that men in the lowest IGF-1 quartile had 2.1 kg less lean mass and 1.4 kg more fat mass than those in the highest quartile, after adjusting for age and BMI [10].

Bone density. IGF-1 stimulates osteoblast activity. The Framingham Osteoporosis Study (N=981) showed that participants in the lowest IGF-1 tertile had a 40% higher risk of hip fracture compared to the highest tertile [11].

Cognitive function. Low IGF-1 has been linked to accelerated cognitive decline in older adults. A prospective study in Neurology (2014, N=3,582) reported that participants in the lowest IGF-1 quartile experienced 1.4x faster decline on the Mini-Mental State Examination over 4 years [12].

Longevity paradox. Here is where the data gets more complex. While low IGF-1 is harmful in the short term (muscle loss, bone loss, cognitive decline), centenarian studies suggest that genetically low IGF-1 signaling may extend lifespan. A 2008 study in Aging Cell (N=384 Ashkenazi Jewish centenarians) found that female centenarians had higher prevalence of IGF-1 receptor mutations that reduced IGF-1 signaling [13]. The clinical takeaway: optimize IGF-1 for function now, but avoid pushing it to supraphysiologic levels chronically.

How to Raise IGF-1 Without Medication

Before reaching for a prescription, consider the modifiable factors that increase IGF-1 production naturally.

Sleep quality. GH is secreted primarily during slow-wave sleep. A study in JCEM (1991) demonstrated that sleep deprivation reduced GH secretion by up to 70%, with proportional drops in IGF-1 over several days [14]. Prioritize 7-9 hours of uninterrupted sleep.

Protein intake. IGF-1 production depends on adequate amino acid availability. Chronically low protein intake (below 0.8 g/kg/day) suppresses hepatic IGF-1 synthesis. A controlled feeding trial in the American Journal of Clinical Nutrition (N=292) found that increasing protein from 0.8 to 1.2 g/kg/day raised IGF-1 by approximately 15% over 3 weeks [15].

Resistance training. Acute bouts of heavy resistance exercise stimulate GH release. Consistent training over 12 weeks has been shown to raise baseline IGF-1 by 10-20% in previously sedentary adults [16].

Correct micronutrient deficiencies. Zinc deficiency suppresses IGF-1. A randomized trial in the American Journal of Clinical Nutrition (N=25) showed that zinc supplementation (25 mg/day) in mildly zinc-deficient men increased IGF-1 by 12% over 20 weeks [17].

How to Lower IGF-1

If your IGF-1 is running high on therapy (or even off therapy), here is what the evidence supports.

Reduce or pause GH peptide therapy. This is the most direct lever. Dose reduction typically normalizes IGF-1 within 2-4 weeks [3].

Caloric restriction lowers IGF-1 significantly. A study from the CALERIE trial (N=218) showed that 25% caloric restriction reduced IGF-1 by 21% over 2 years, but only when protein intake also dropped [18]. Protein-sufficient caloric restriction does not reliably lower IGF-1.

Reduce dairy and animal protein. Observational data from the European Prospective Investigation into Cancer and Nutrition (EPIC, N=4,731) found that vegans had 9% lower IGF-1 than omnivores [19]. The effect size is modest. This is a secondary strategy, not a primary one.

Address insulin resistance. Hyperinsulinemia increases hepatic IGF-1 production by upregulating GH receptor expression in the liver [8]. Metformin, GLP-1 receptor agonists, and weight loss all reduce circulating insulin, which can secondarily lower IGF-1.

When and How to Retest IGF-1

Timing matters. Draw the sample fasted (10-12 hours), in the morning, and at least 24 hours after your last GH peptide injection.

During initial titration, recheck IGF-1 every 4-6 weeks until you reach a stable dose. Once stable, the AACE guideline recommends monitoring every 6-12 months [5]. If you change your dose, switch peptides, start a new medication that could interact (oral estrogen, glucocorticoids, thyroid hormone), or undergo significant weight change, recheck within 4-6 weeks.

Order IGFBP-3 alongside IGF-1 if results seem discordant with clinical status. IGFBP-3 is GH-dependent and provides a confirmatory signal. A ratio of IGF-1 to IGFBP-3 that falls outside normal suggests assay interference or a binding protein abnormality [2].

Track your results over time. A single IGF-1 value is useful, but the trend across 3-4 draws tells a far richer story. Your clinician should be plotting your IGF-1 trajectory against the age-adjusted range, adjusting the protocol when the curve drifts outside the target window. The goal is not a single perfect number. The goal is a stable IGF-1 in the upper half of your age-specific reference range, held there for months and years without exceeding the ceiling.